Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04761601 · ClinicalTrials.gov registry record · Phase 1
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by 1200 Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04761601 is a Phase 1 study that was terminated before completion, run by 1200 Pharma. The registered enrollment target is 32 participants.
The verdict
NCT04761601, a Phase 1 study, was terminated before completion, sponsored by 1200 Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-01-097 in patients with advanced solid tumors.
Interventions
- DRUG Paclitaxel
- DRUG Gemcitabine
- DRUG UCT-01-097
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2024-02-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04761601
The ClinicalTrials.gov registry entry for NCT04761601 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 1200 Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT04761601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04761601 about?
NCT04761601 is a clinical study titled "First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors". This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-01-097 in patients with advanced solid tumors.
What is the current status of trial NCT04761601?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2021-03-03. Estimated completion is 2024-02-29.
What interventions are being tested in trial NCT04761601?
The interventions under investigation include: Paclitaxel (DRUG), Gemcitabine (DRUG), UCT-01-097 (DRUG).
Who is sponsoring clinical trial NCT04761601?
This trial is sponsored by 1200 Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.